New Rules on Centralised Authorisation for Device Trials in Germany Continue to Frustrate Industry
This article was originally published in RAJ Devices
Medical technology firms in Germany see recent regulatory and political changes in their country as largely positive, with one or two exceptions. Tobias Weiler, head of the medical technology department of industry association Spectaris, tells Ashley Yeo about his hopes and fears for the industry.
You may also be interested in...
While personal data security must be balanced againt the right to health, winning “trust” is the key to taking AI adoption to the next stage, says a new report focused on the European market.
The latest guidance from the UK devices regulator fills in some of the information gaps for companies addressing the Northern Ireland and EU27 markets after this year, seen through the lens of Brexit.
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.